Do you want to read an article? Please log in or register.
Gemcitabine versus Bacillus Calmette-Guerin for Intravesical Therapy in Treatment-Naïve Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
Genitourinary Cancer
Related content
COMMENTED
Genitourinary Cancer
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group results
★ 1
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
BJU Int
Scilipoti P, Longoni M, de Angelis M, Zaurito P, Massiet A, Dutto D, Soria F, Álvarez-Maestro M, Bazán AA, Pradere B, Klatte T, Contieri R, Hurle R, Krajewski W, Subiela JD, Pichler R, Szostek A, Marcq G, Elena JLR, Aranda J, Gontero P, Rouprêt M, Shariat SF, Necchi A, Montorsi F, Briganti A, Xylinas E, Moschini M, EuroGemDoce Study Group Collaborators, European Association of Urology ‐ Young Academic Urologists (EAU‐YAU), Urothelial Carcinoma Working Group
doi: 10.1111/bju.16645
Genitourinary Cancer
Predicting response to intravesical BCG in high-risk non-muscle invasive bladder cancer using an artificial intelligence-powered pathology assay: development and validation in an international 12 center cohort
J Urol
Lotan Y, Krishna V, Abuzeid WM, Launer B, Chang SS, Krishna V, Shingi S, Gordetsky JB, Gerald T, Woldu S, Shkolyar E, Hayne D, Redfern A, Spalding L, Stewart C, Eyzaguirre E, Imtiaz S, Narayan VM, Packiam VT, O'Donnell MA, Li R, Baekelandt L, Joniau S, Zuiverloon T, Fernandez MI, Schultz M, Hensley PJ, Allison D, Taylor JA, Hamza A, Kamat A, Nimgaonkar V, Sonawane S, Miller DL, Watson D, Vrabac D, Joshi A, Shah JB, Williams SB
doi: 10.1097/JU.0000000000004278
Genitourinary Cancer
Real-word outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trial
BJU Int
Conroy S, Jubber I, Noon AP, Rosario DJ, Griffin J, Morgan S, Hubbard R, Kennish S, Mitchell S, Venugopal S, Linton K, Rajasundaram R, Hussain SA, Catto JWF
doi: 10.1111/bju.16516
Genitourinary Cancer
Follow-up strategies after trimodal treatment for muscle-invasive bladder cancer: a systematic review
World J Urol
Kaufmann E, Aeppli S, Arnold W, Balermpas P, Beyer J, Bieri U, Cathomas R, de Bari B, Dressler M, Engeler DS, Erdmann A, Gallina A, Gomez S, Guckenberger M, Herrmann TRW, Hermanns T, Ilaria L, John H, Kessler TM, Klein J, Laouiti M, Lauffer D, Mattei A, Müntener M, Nguyen D, Niederberger P, Papachristofilou A, Prause L, Reinhardt K, Salati E, Sèbe P, Shelan M, Strebel R, Templeton AJ, Vogl U, Wettstein MS, Zihler D, Zilli T, Zwahlen D, Roth B, Fankhauser C
doi: 10.1007/s00345-024-05196-7
SPECIAL REPORT
Genitourinary Cancer
EAU Annual Congress 2024: adjuvant therapy for high-risk muscle-invasive urothelial carcinoma with PD-L1 expression ≥ 1
Lung, Respiratory and Thoracic Cancer
The optimal treatment for patients with stage I non-small cell lung cancer: minimally invasive lobectomy versus stereotactic ablative radiotherapy - a nationwide cohort study
Lung Cancer
de Ruiter JC, van der Noort V, van Diessen JNA, Smit EF, Damhuis RAM, Hartemink KJ, ESLUNG group
doi: 10.1016/j.lungcan.2024.107792
Genitourinary Cancer
European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update
Eur Urol
Gontero P, Birtle A, Capoun O, Compérat E, Dominguez-Escrig JL, Liedberg F, Mariappan P, Masson-Lecomte A, Mostafid HA, Pradere B, Rai BP, van Rhijn BWG, Seisen T, Shariat SF, Soria F, Soukup V, Wood R, Xylinas EN
doi: 10.1016/j.eururo.2024.07.027
Myelodysplastic syndromes
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
Lancet Haematol
Díez-Campelo M, López-Cadenas F, Xicoy B, Lumbreras E, González T, Del Rey González M, Sánchez-García J, Coll Jordà R, Slama B, Hernández-Rivas JÁ, Thepot S, Bernal T, Guerci-Bresler A, Bargay J, Amigo ML, Preudhomme C, Fenwarth L, Platzbecker U, Götze KS, Arar A, Toribio S, Del Cañizo C, Hernández-Rivas JM, Fenaux P
doi: 10.1016/S2352-3026(24)00142-X
ASCO 2024
Gynecologic Cancer